On October 2, 2025, Mr. Morgan was convicted as defined in section 306(l)(1) of the FD&C Act, in the U.S. District Court for the Western District of Pennsylvania, when the court accepted his plea of guilty and entered judgment against him for the felony offense of misbranding drugs in interstate commerce with intent to defraud in violation of 21 U.S.C. 331(k) and 333(a)(2) (sections 301(k) and 303(a)(2) of the FD&C Act). The underlying facts supporting the conviction are as follows:

As contained in the Indictment from Mr. Morgan's case, to which he pled guilty in relevant part, Mr. Morgan sold what he purported to be ''Prop Xanax'' pills to the general public through the website he operated, *corneliusrxprops.com*, and several associated websites. However, despite labeling these pills as ''prop'' in an attempt to claim that these were not drugs subject to regulation by FDA, Mr. Morgan knew that the pills he sold would be consumed by his customers. Also, although Mr. Morgan purported to sell ''Xanax,'' some of the customers who purchased the drugs through his websites actually received bromazolam. Mr. Morgan obtained the bromazolam he sold in interstate commerce, including by importing it from China. The bromazolam was misbranded because it was manufactured, prepared, and processed in a facility not registered with the Secretary of Health and Human Services, was disbursed without adequate directions for use, and had labeling that was misleading.

FDA sent Mr. Morgan, by certified mail, on March 18, 2026, a notice proposing to debar him for a 5-year period from importing or offering for import any drug into the United States. The proposal was based on a finding under section 306(b)(3)(C) of the FD&C Act that Mr. Morgan's felony conviction under federal law for misbranding drugs in interstate commerce with intent to defraud in violation of 21 U.S.C. 331(k) and 333(a)(2) was for conduct relating to the importation of any drug or controlled substance into the United States because Mr. Morgan imported and introduced misbranded drugs in interstate commerce with intent to defraud. In proposing a debarment period, FDA weighed the considerations set forth in section 306(c)(3) of the FD&C Act that the Agency considered applicable to Mr. Morgan's offense and concluded that the offense warranted the imposition of a 5-year period of debarment.

The proposal informed Mr. Morgan of the proposed debarment and offered him an opportunity to request a hearing, providing him 30 days from the date of receipt of the letter in which to file the request, and advised him that failure to request a hearing constituted a waiver of the opportunity for a hearing and of any contentions concerning this action. Mr. Morgan received the proposal and notice of opportunity for a hearing on March 30, 2026. Mr. Morgan failed to request a hearing within the timeframe prescribed by regulation and has, therefore, waived his opportunity for a hearing and waived any contentions concerning his debarment (21 CFR part 12).

II. Findings and Order

Therefore, the Division of Field Enforcement Director, Office of Inspections and Investigations, under section 306(b)(3)(C) of the FD&C Act, under authority delegated to the Director, Division of Enforcement, finds that Mr. Andrew Jonathan Morgan has been convicted of a felony under federal law for conduct relating to the importation into the United States of any drug or controlled substance. FDA finds that the offense should be accorded a debarment period of 5 years as provided by section 306(c)(2)(A)(iii) of the FD&C Act.

As a result of the foregoing finding, Mr. Morgan is debarred for a period of 5 years from importing or offering for import any drug into the United States, effective (see **DATES**). Pursuant to section 301(cc) of the FD&C Act (21 U.S.C. 331(cc)), the importing or offering for import into the United States of any drug by, with the assistance of, or at the direction of Mr. Morgan during his period of debarment is a prohibited act.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–12167 Filed 6–16–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, June 30, 2026, 09:00 a.m. to July 01, 2026, 06:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on June 01, 2026, 91 FR 32404, FR Doc No. 2026–10931.

This meeting is being amended to change the contact person from Caterina Bianco to Jennifer Sanders, Ph.D. Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD, Tel. 301–496–3553. The meeting is closed to the public.

Dated: June 12, 2026.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–12156 Filed 6–16–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA–OD–25–012: Informatics, Coordination and Service Center for the Mutant Mouse Resource and Research Centers.

Date: July 14, 2026.

Time: 10:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 6188 MSC 7804, Bethesda, MD 20892, 301–435–1267, *belangerm@csr.nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Infrastructure for Drug Development and Outreach to Aid in Medication Repurposing for Substance Use Disorders (SUDs).

Date: July 14, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.